J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

The effect of intravenous bumetanide in man with normal and low renal function

MG White

Bumetanide was administered intravenously to four groups of patients with varying levels of glomerular filtration rate (average 10 to 108 ml/min/1.73 m2 B.S.A.). The dose of bumetanide was either 0.25, 0.5, 1.0, or 2.0 mg administered by intravenous "push." The intravenous administration produced a prompt and marked increase in sodium, chloride, and calcium excretion. The effect was brief, lasting 30 to 60 minutes, but persisted to some extent with the 2.0 mg dose beyond 120 minutes. There was no effect on phosphate excretion or on the parameters of net acid excretion.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American College of Clinical Pharmacology